https://orcid.org/0000-0003-2189-5010
Figures & data
Figure 1 The workflow of the study design.
Table 1 Clinical Characteristics of Study Subjects at Baseline and at the Four-Year Follow-Up (n=233)
Table 2 Frequencies of the GC rs7041 and the GC rs4588 Genotypes in the Study Cohort
Figure 2 Secreted VDBP is upregulated in the sputum of smokers with COPD.
Notes: (A) Representative 2D gel of the sputum from a characteristic COPD patient (stage II). Altered protein spots of VDBP indicated by 1 and 2. Histogram corresponding to the spot numbers indicates the protein levels in non-smokers (NS), smokers (S) and COPD patients (C). (B) A representative mass spectrum (MS) of the altered VDBP. Peptides marked with grey arrows matched to all three isoforms whereas the black arrows matched only to isoforms 1 and 3. The schematic presentation of VDBP shows the signal peptide (SP) and the sequence coverage of the spot-specific peptides detected by MS. The N-terminal peptide of the mature VDBP indicated by an asterisk. (C) Western blot of the sputum from non-smokers (NS, n = 7) and smokers with COPD stage II (COPD, n = 7).
Figure 3 Levels of VDBP and 25-OH vitamin D at baseline for (A) sputum VDBP, (B) plasma VDBP and (C) plasma 25-OH vitamin D.
Figure 4 Sputum levels of VDBP according to the GC rs7041 and rs4588 at baseline for (A) GC rs7041, (B) GC rs74588 and (C) GC1S/1S in rs7041/rs74588.
Table 3 Correlation Between Sputum VDBP and Clinical Characteristics at Baseline and Follow-Up for Different Genotypes
Table 4 Multivariate Regression Analysis of Predicted FEV1% at Follow-Up as the Dependent Variable Among Subjects with Different Genotypes
Figure 5 Correlation between sputum VDBP and predicted FEV1% at follow-up based on GC1S/1S genotype.
